Press Releases

RNA Solutions is the platform that offers services on the revolutionizing study of RNA, targeting both coding and non-coding RNAs of different physiological functions. The scientists at CD Genomics are ready to help detect various types of RNA via meticulous and integrative approaches. To further enrich its service types, the company recently announced to add Ribo-Seq to its offerings.

Ribo-Seq, also known as ribosome footprinting, is a method for determining which mRNAs are actively translated by using specialized messenger RNA sequencing. Ribo-Seq creates a translatome, which is a "global snapshot" of all the active ribosomes in a cell at a specific time. Unlike RNA-Seq, which reads all mRNAs of a specific sequence present in a sample, Ribo-Seq targets only mRNA sequences protected by the ribosome throughout the process of decoding by translation.

“Our Ribo-Seq service is a next-generation sequencing based transcriptomic research technique that measures translation comprehensively and quantitatively. It can detect the precise positions of ribosomes to determine which mRNAs are being actively translated, which allows for the profiling of the active ribosomes in a cell at a particular moment, as well as the location of the translation initiation sites, the complement of translated ORFs, the specific locations of ribosomes on the mRNA, and the translation rate of ribosomes,” said the senior scientist at CD Genomics.

Ribo-Seq provided by CD Genomics has three main uses:

1) Ribo-Seq enables researchers to identify the location of the translation start site, the complement of translated ORF in cells or tissues, the distribution of ribosomes on messenger RNA, and the speed of translation ribosomes.

2) Combining ribosome analysis with other technologies such as IP or ChIP can clarify how and when the newly synthesized protein folds. Using the footprint provided by Ribo-Seq, specific ribosomes related to molecular chaperones and other factors can be purified.

3) Ribo-Seq can also be used to estimate translation efficiency, which represents protein synthesis. For this application, Ribo-Seq and matching RNA-Seq data will be generated. The translation efficiency can then be calculated as the ribosome occupancy of each gene while controlling its RNA expression. This method can be combined with mass spectrometry methods for proteome analysis.

“CD genomics provides a ribosome-profiling strategy that is based on the deep sequencing of ribosome-protected mRNA fragments and enables genome-wide investigation of translation with sub cordon resolution. Using nuclease digestion, the ribosome position and the translated message can be precisely determined by analyzing the protected ~30-nt area of the mRNA template. We believe our service will move your research forward,” commented the Vice President of CD Genomics.

About CD Genomics

CD Genomics has the most advanced next-generation sequencing, microarray, and mass spectrometry technology platforms, providing reliable services for pharmaceutical, biotechnology companies, academia and government agencies, and enjoys a high reputation. CD Genomics is proud to meet the needs of domestic and foreign customers, with customers in more than 50 countries and regions.

Contact

Address: Shirley, NY 11967, USA

Email: contact@cd-genomics.com